Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-oxo-4-androstene-17beta-carboxylic acid is a steroidal small molecule and active pharmaceutical ingredient (API) intermediate produced by Jiangsu Jiaerke Pharmaceuticals. It serves as a critical structural precursor in the industrial synthesis of various steroid-based medications. Most notably, it is a key intermediate in the production of 5-alpha reductase inhibitors such as finasteride and dutasteride, which are used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia. As an intermediate, its primary role is as a chemical building block in pharmaceutical manufacturing rather than as a finished therapeutic agent. It is typically supplied as a bulk API for further chemical transformation into final drug products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-oxo-4-androstene-17beta-carboxylic acid.